Basic Search  |  Summaries  |  Advanced SearchPenalty: £37,100,000
Year: 2021
Date: 29 July, 2021
Offence Group: competition-related offences
Offence Type: price-fixing or anti-competitive practices
Violation Description: The Competition and Markets Authority (CMA) found that from 2009 until 2017 the pharmaceutical company Advanz charged excessive and unfair prices for supplying liothyronine tablets which are used to treat thyroid hormone deficiency. The agency also fined two private equity firms, HGCapital and Cinven, that previously owned parts of the business.
Agency: Competition and Markets Authority
HQ Country of Parent: United Kingdom
Ownership Structure of Parent: privately held
Major Industry of Parent: private equity (including portfolio companies)
Specific Industry of Parent: private equity (including portfolio companies)
Source of Data: (click here)
Source Notes: Cinven’s fine was reduced to £37.1 million on appeal in 2023.